TFL: Thulium Fiber Laser Prospective Trial

Sponsor
Centre hospitalier de l'Université de Montréal (CHUM) (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05814133
Collaborator
University of British Columbia (Other), Columbia University (Other), University of California, San Diego (Other), Mayo Clinic (Other), Ohio State University (Other), Vanderbilt University (Other), The Cleveland Clinic (Other)
150
1
1
15
10

Study Details

Study Description

Brief Summary

This is a multi-center, prospective clinical trial to assess the effect of TFL for the lithotripsy of kidney stones.

Condition or Disease Intervention/Treatment Phase
  • Device: Thulium Fiber Laser
N/A

Detailed Description

Flexible ureteroscopy is considered the first-line therapy for renal stones < 2 cm. The Holmium: YAG laser (Ho:YAG) is established as gold standard in urology practice. Despite its limitations, it is widely used to break stones into fragments small enough to remove or pass spontaneously through the ureter. Advances in the understanding of laser energy delivery have led to the recent commercialization of the 'Thulium Fiber Laser' (TFL) with unique characteristics and promising improvements of ablation efficiency, dusting capacity, operating time and deflection. A a multi-center, prospective clinical trial to further assess those advantages for the lithotripsy of kidney stones will be conducted.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Clinical Trial To Evaluate The Thulium Fiber Laser For The Ureteroscopic Treatment Of Nephrolithiasis
Anticipated Study Start Date :
Apr 15, 2023
Anticipated Primary Completion Date :
Apr 15, 2024
Anticipated Study Completion Date :
Jul 15, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lithotripsy

Ureteroscopy with lithotripsy using the Thulium Fiber Laser

Device: Thulium Fiber Laser
Thulium Fiber Laser will be used to break renal stones < 2 cm into fragments small enough to remove or pass spontaneously through the ureter.

Outcome Measures

Primary Outcome Measures

  1. Mean total operative time [during the procedure]

    Total operative time during the ureteroscopic treatment of renal stones using a laser dusting technique.

Secondary Outcome Measures

  1. Rate of stone retropulsion [during the procedure]

    Review of the procedure video recording to assess stone retropulsion occurence during stone lithotripsy

Other Outcome Measures

  1. Mean length of hospitalization [From day and time of admission to day and time of discharge]

    Length of hospitalization (in days) for the procedure will be recorded for each patient

  2. Rate of postoperative complications [at 6 weeks]

    Medical chart review will be done to assess the occurence of post-operative complications

  3. Rate of stone free status [at 6 weeks]

    Post-operative CT imaging will be reviewed to assess the occurence of ''stone free status''

  4. Rate of need for ancillary procedures [at 6 weeks]

    Medical chart review will be done to assess the occurence of an additional ureteroscopy need to treat patients

  5. Mean perceived workload score [immediately after the procedure]

    Effects of TFL technology on reducing surgeon perceived workload will be assessed by completing the National Aeronautics and Space Administration (NASA) Task Load Index. The tool allows to determine the subjective mental workload (MWL) of a participant while they are performing a task.The participants self-rate on a scale of 1 (low) to 20 (high). The higher the score, the worst is the outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Solitary renal stone 8 to 20 mm in size or in the case of multiple stones the conglomerate diameter of 8-20 mm is required

  • Must be a suitable operative candidate for flexible ureteroscopy per urologic guidelines

  • Must be 18 years or older

  • Must be able to give consent

  • Bilateral ureteroscopy will be permitted but only the first side will be included in the study

Exclusion Criteria:
  • Concomitant stones in the ureter

  • Prior ipsilateral upper urinary tract reconstructive procedures or history of ipsilateral ureteral stricture

  • Prior radiotherapy to the abdomen or pelvis

  • Neurogenic bladder or spinal cord injury

  • Pregnancy

  • Untreated Urinary Tract Infection (UTI)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier de l'Université de Montréal Montreal Quebec Canada H2X 0A9

Sponsors and Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)
  • University of British Columbia
  • Columbia University
  • University of California, San Diego
  • Mayo Clinic
  • Ohio State University
  • Vanderbilt University
  • The Cleveland Clinic

Investigators

  • Principal Investigator: Naeem Bhojani, MD, Centre hospitalier de l'Université de Montréal (CHUM)

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier:
NCT05814133
Other Study ID Numbers:
  • 2023-11370
First Posted:
Apr 14, 2023
Last Update Posted:
Apr 14, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM)
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2023